Navigation Links
As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP

Percentage of Clinicians Performing hsCRP Testing Will Increase Dramatically Over the Next Six Months, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, as a result of the JUPITER clinical trial, 65 percent of surveyed managed care organizations' (MCO) pharmacy directors say they will reimburse AstraZeneca's Crestor for healthy patients with elevated levels of high sensitivity C-reactive protein (hsCRP). The JUPITER trial enrolled apparently healthy subjects without high LDL cholesterol but with elevated hsCRP and randomized subjects to receive Crestor or placebo. Trial data showed a 44 percent reduction in major cardiovascular events and reduced all-cause mortality by 20 percent among participants receiving Crestor.

The new Physician & Payer Forum report entitled The JUPITER Trial: Will Physicians and Payers Support a Change in Statin Prescribing? finds that 15 percent of surveyed MCO pharmacy directors will grant Crestor more favorable tier status in light of the trial. Crestor is currently on tier one of only 10 percent of surveyed MCO private health plans, while Pfizer's Lipitor is on tier one of 30 percent of surveyed MCO plans. Additionally, among Medicare prescription drug plans, Crestor has the highest rate of coverage among branded statins.

"Our findings suggest that in response to the JUPITER trial data, many clinicians will start using a statin ahead of diet and exercise changes," said Decision Resources Analyst Graeme Green, Ph.D. "Most of these clinicians will favor Crestor for these patients, indicating that AstraZeneca will benefit the most from such a trend."

The report finds that, in response to JUPITER trial data, the percentage of clinicians performing hsCRP testing will increase dramatically over the next six months among patients with and without cardiovascular risk factors. Surveyed clinicians anticipate that the percentage of patients with no cardiovascular risk factors tested for elevated hsCRP will increase from 5 percent in July 2008, to 26 percent in July 2009. The percentage of patients with two or more cardiovascular risk factors tested by primary care physicians for hsCRP will increase from 16 percent in July 2008 to 40 percent in July 2009.

The JUPITER Trial: Will Physicians and Payers Support a Change in Statin Prescribing? is based on a U.S. survey of 71 primary care physicians, 72 cardiologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                           Decision Resources, Inc.
    Christopher Comfort                          Elizabeth Marshall
    781-296-2597                                 781-296-2563            

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
2. XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress
3. Insulet Corporation to Report Fourth Quarter and Full Year 2008 Financial Results on Thursday, March 5, 2009
4. WebMD Announces Fourth Quarter Financial Results
5. Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009
6. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
7. HLTH Corporation Announces Fourth Quarter Financial Results
8. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
9. Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Fourth Quarter 2008 Earnings Results Webcast
10. QLT Announces Fourth Quarter and Year End 2008 Results
11. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology: